Urothelial Ca immunotherapy approved for first-line use – ModernMedicine
|
Urothelial Ca immunotherapy approved for first-line use
ModernMedicine The regulatory agency's decision makes atezolizumab the only cancer immunotherapy agent approved for initial treatment of urothelial carcinoma in patients who are ineligible for cisplatin. In May 2016, atezolizumab became the first immunotherapy agent … |
